Enanta Pharmaceuticals Ownership | Who Owns Enanta Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Enanta Pharmaceuticals Ownership Summary


Enanta Pharmaceuticals is owned by 100.04% institutional investors, 6.09% insiders. Farallon capital management is the largest institutional shareholder, holding 9.89% of ENTA shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.97% of its assets in Enanta Pharmaceuticals shares.

ENTA Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockEnanta Pharmaceuticals100.04%6.09%-6.13%
SectorHealthcare Stocks 49.73%8.84%41.43%
IndustryBiotech Stocks 47.04%8.74%44.21%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Farallon capital management2.10M9.89%$27.17M
Vanguard group1.93M9.13%$25.09M
Blackrock1.85M8.72%$23.96M
Morgan stanley1.46M6.88%$18.89M
Krensavage asset management1.25M5.91%$16.23M
Armistice capital1.10M5.17%$14.22M
Caligan partners lp1.04M4.92%$13.53M
Marshall wace, llp928.36K4.38%$12.04M
Acadian asset management849.42K4.01%$11.01M
Northern trust845.12K3.99%$10.96M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Krensavage asset management1.25M7.45%$16.23M
Caligan partners lp1.04M3.16%$13.53M
Soleus capital management799.55K0.91%$10.37M
Sio capital management177.00K0.62%$2.30M
Tang capital management300.00K0.40%$3.89M
Armistice capital1.10M0.18%$14.22M
Boothbay fund management483.28K0.15%$6.27M
Farallon capital management2.10M0.13%$27.17M
Portland global advisors33.19K0.06%$430.41K
Pdt partners36.24K0.04%$470.07K

Top Buyers

HolderShares% AssetsChange
Soleus capital management799.55K0.91%219.00K
Caligan partners lp1.04M3.16%184.82K
Krensavage asset management1.25M7.45%126.75K
Boothbay fund management483.28K0.15%94.68K
Bank of america corp /de/595.91K0.00%79.55K

Top Sellers

HolderShares% AssetsChange
Morgan stanley1.46M0.00%-588.59K
Assenagon asset management426.56K0.01%-157.10K
Armistice capital1.10M0.18%-140.00K
Northern trust845.12K0.00%-88.24K
Two sigma investments, lp184.56K0.01%-72.75K

New Positions

HolderShares% AssetsChangeValue
Norges bank40.70K0.00%40.70K$527.88K
Corebridge financial10.81K0.00%10.81K$140.17K
Mirae asset global etfs9.76K0.00%9.76K$126.61K
Srs capital advisors128.000.00%128.00$1.66K
Picton mahoney asset management79.00-79.00$1.00K

Sold Out

HolderChange
Nelson, van denburg & campbell wealth management group-4.00
Innealta capital-16.00
Allworth financial lp-86.00
Signaturefd-163.00
Comerica bank-333.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202411111.00%21,189,162-3.74%1000.93%5627.27%32-27.27%
Jun 30, 2024100-6.54%22,011,926-1.25%1030.94%444.76%44-12.00%
Mar 31, 20241071.90%22,290,57011.98%1051.18%42-22.22%5016.28%
Dec 31, 2023105-19.85%19,906,154-1.08%941.03%54-22.86%43-2.27%
Sep 30, 2023131-1.50%20,122,617-0.08%951.05%70-9.09%4429.41%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv629.60K2.97%-
iShares Russell 2000 ETF524.38K2.47%-1.18K
Vanguard Strategic Small-Cap Equity Inv300.76K1.42%30.09K
Vanguard Institutional Extnd Mkt Idx Tr281.61K1.33%-
Columbia Small Cap Value I A268.43K1.27%67.75K
Vanguard VIF Small Co Gr253.37K1.20%-
Fidelity Small Cap Index203.26K0.96%-5.66K
Columbia Small Cap Value I200.68K0.95%200.68K
iShares Russell 2000 Value ETF188.38K0.89%-
UBS (Lux) EF Biotech (USD) P-acc182.00K0.86%-3.20K

Recent Insider Transactions


DateNameRoleActivityValue
Dec 06, 2024Kieffer Tara Lynn Chief Product Strategy OfficerSell$18.40K
Dec 06, 2024Luu Brendan Chief Business OfficerSell$18.40K
Dec 06, 2024Rottinghaus Scott T. Chief Medical OfficerSell$6.98K
Dec 06, 2024Or Yat Sun Chief Scientific OfficerSell$20.88K
Dec 06, 2024MELLETT PAUL J Chief Fin. & Admin OfficerSell$20.88K

Insider Transactions Trends


DateBuySell
2024 Q4--
2024 Q3-3
2024 Q2-1
2024 Q1--
2023 Q4-8

ENTA Ownership FAQ


Who Owns Enanta Pharmaceuticals?

Enanta Pharmaceuticals shareholders are primarily institutional investors at 100.04%, followed by 6.09% insiders and -6.13% retail investors. The average institutional ownership in Enanta Pharmaceuticals's industry, Biotech Stocks , is 47.04%, which Enanta Pharmaceuticals exceeds.

Who owns the most shares of Enanta Pharmaceuticals?

Enanta Pharmaceuticals’s largest shareholders are Farallon capital management (2.1M shares, 9.89%), Vanguard group (1.93M shares, 9.13%), and Blackrock (1.85M shares, 8.72%). Together, they hold 27.75% of Enanta Pharmaceuticals’s total shares outstanding.

Does Blackrock own Enanta Pharmaceuticals?

Yes, BlackRock owns 8.72% of Enanta Pharmaceuticals, totaling 1.85M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 23.96M$. In the last quarter, BlackRock increased its holdings by 8.46K shares, a 0.46% change.

Who is Enanta Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Krensavage asset management is Enanta Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 7.45% of its assets in 1.25M Enanta Pharmaceuticals shares, valued at 16.23M$.

Who is the top mutual fund holder of Enanta Pharmaceuticals shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Enanta Pharmaceuticals shares, with 2.97% of its total shares outstanding invested in 629.6K Enanta Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools